By using wearable devices to monitor and record the physiological data changes and health outcomes (incidence and severity of high-altitude illnesses) of high-altitude migrants at different stages (pre-entry, acute/chronic high-altitude phases, and de-acclimatization phase), and referencing previous cohort studies on high-altitude populations, the study aims to provide a basis for developing personalized health assessment protocols for high-altitude migrants. The formulated assessment protocols and standards will then be validated.
Men and women aged ≥18;
Those living in plains and preparing to move to the plateau for a short-term or medium-term period;
Can understand the research requirements and be willing to sign a written informed consent form (ICF).
Past history of contraindicated plateau travel: such as advanced COPD (FEV₁<30% of the expected value or requires continuous oxygen therapy), advanced cystic fibrosis (FEV₁<30% of the expected value or requires continuous oxygen therapy), advanced restricted pulmonary disease (FEV₁<50% of the expected value or requires continuous oxygen therapy), decompensated heart failure, high-risk pregnancy, myocardial infarction or stroke occurred within 90 days, poorly controlled epilepsy, pulmonary hypertension (PASP>90mmHg), sickle cell anemia, unstable angina pectoris, high-risk cerebrovascular abnormalities that have not been treated, etc.
Recruit those who live in plains and prepare to move to the plateau in the short term or medium term.
Cohort
Prospective
Not listed
Rates of high altitude sickness and related diseases.
Early diagnosis rates of acute and chronic altitude sickness and related diseases induced or aggravated by the plateau population in migrant plateau populations.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
